US FDA action on drug shortages yields results, agency improves user fee goals
This article was originally published in SRA
Executive Summary
The first week in May brought mostly good news for the US Food and Drug Administration. Agency chief Margaret Hamburg touted the FDA’s progress in greatly reducing drug shortages, while a congressional watchdog also extolled regulators' improvement in meetings user fee performance goals, although review times increased slightly. The Institute of Medicine, however, had a bone to pick with the agency about its post-approval monitoring practices.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.